Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy
Open Access
- 9 May 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (5) , e008104
Abstract
Background Tumor-associated antigens and their derived peptides constitute an opportunity to design off-the-shelf mainline or adjuvant anti-cancer immunotherapies for a broad array of patients. A performant and rational antigen selection pipeline would lay the foundation for immunotherapy trials with the potential to enhance treatment, tremendously benefiting patients suffering from rare, understudied cancers. Methods We present an experimentally validated, data-driven computational pipeline that selects and ranks antigens in a multipronged approach. In addition to minimizing the risk of immune-related adverse events by selecting antigens based on their expression profile in tumor biopsies and healthy tissues, we incorporated a network analysis-derived antigen indispensability index based on computational modeling results, and candidate immunogenicity predictions from a machine learning ensemble model relying on peptide physicochemical characteristics. Results In a model study of uveal melanoma, Human Leukocyte Antigen (HLA) docking simulations and experimental quantification of the peptide–major histocompatibility complex binding affinities confirmed that our approach discriminates between high-binding and low-binding affinity peptides with a performance similar to that of established methodologies. Blinded validation experiments with autologous T-cells yielded peptide stimulation-induced interferon-γ secretion and cytotoxic activity despite high interdonor variability. Dissecting the score contribution of the tested antigens revealed that peptides with the potential to induce cytotoxicity but unsuitable due to potential tissue damage or instability of expression were properly discarded by the computational pipeline. Conclusions In this study, we demonstrate the feasibility of the de novo computational selection of antigens with the capacity to induce an anti-tumor immune response and a predicted low risk of tissue damage. On translation to the clinic, our pipeline supports fast turn-around validation, for example, for adoptive T-cell transfer preparations, in both generalized and personalized antigen-directed immunotherapy settings.Keywords
Funding Information
- Manfred-Roth-Stiftung (n/a)
- Deutsche Forschungsgemeinschaft (324392634, 447268119)
- Bundesministerium für Forschung, Technologie und Raumfahrt (01ZX1905A, 01ZX1905B, 161L0244A, 16LW0338K)
- Deutsche Krebshilfe (110182, 70114489)
- Horizon Europe research and innovation (101057250)
- Hiege-Stiftung (n/a)
- Forschungsstiftung Medizin am Universitätsklinikum Erlangen (n/a)
This publication has 50 references indexed in Scilit:
- Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada diseaseInternational Ophthalmology, 2007
- Generation of peptide–MHC class I complexes through UV-mediated ligand exchangeNature Protocols, 2006
- Bystander elimination of antigen loss variants in established tumorsNature Medicine, 2004
- HLA class I antigen loss, tumor immune escape and immune selectionVaccine, 2002
- Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma:In vivopersistence, migration, and antitumor effect of transferred T cellsProceedings of the National Academy of Sciences, 2002
- Tyrosinase Stabilization by Tyrp1 (the brown Locus Protein)Journal of Biological Chemistry, 1998
- Establishment and characterization of an uveal‐melanoma cell lineInternational Journal of Cancer, 1995
- Organization and sequence of the human P gene and identification of a new family of transport proteinsGenomics, 1995
- Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.Proceedings of the National Academy of Sciences, 1994
- Prediction of protein antigenic determinants from amino acid sequences.Proceedings of the National Academy of Sciences, 1981